Gefitinib ('Iressa', ZD1839): the patients' experience

By Goss G.  

EJC Supplements, Vol. 1, Iss. 8, 2003-10 ,pp. : 29-33

Elsevier

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

By Hiscox Stephen   Morgan Liam   Barrow Denise   Dutkowski Carol   Wakeling Alan   Nicholson Robert  

Clinical and Experimental Metastasis, Vol. 21, Iss. 3, 2004-05 ,pp. : 201-212

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience

By Hotta Katsuyuki   Ueoka Hiroshi   Kiura Katsuyuki   Tabata Masahiro   Ogino Atsuko   Umemura Shigeki   Harita Shingo   Gemba Kenichi   Yonei Toshiro   Bessho Akihiro   Maeda Tadashi   Tanimoto Mitsune  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 717-722

Informa Healthcare

Access to resources Recommend Favorite